Angela Rose Brannon

Angela Rose Brannon, PhD


My Role at MSK

Areas of Expertise

My Specialties

  • Clinical Cancer Genomics
  • Molecular Oncology
  • Translational Cancer Biology

About Me

What I Do at MSK
  • Director, Clinical Bioinformatics
Get To Know Me

As the Director of Clinical Bioinformatics, I focus my clinical efforts on ensuring that the genomic results returned to our patients are of the highest quality possible. 

On the research and development side, I am actively involved in the development and validation of updated or new DNA and RNA sequencing assays. In collaborations with pathologists, the Early Drug Development Service, and/or Global Biomarker Development Program, we are also analyzing patient data to develop improved algorithms for identifying patient cohorts who will better respond to various treatment modalities.


My Role at MSK

A bioinformatician (BY-oh-in-for-ma-ZIH-shun) is a scientist who makes computer software tools that are used to analyze genetic (DNA and RNA) data.

Areas of Expertise

My Specialties

  • Clinical Cancer Genomics
  • Molecular Oncology
  • Translational Cancer Biology
Education & Honors


  • PhD, University of North Carolina


  • Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Contact and Location

Dr. Brannon sees patients at one location.

Office Phone
New York, NY
1275 York Avenue New York NY 10065

Looking to see a doctor at a different location? See all MSK locations.


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Molecular Diagnostics doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, Sadowska J, Murphy BJ, Baldi T, Johnson I, Ptashkin R, Hasan M, Srinivasan P, Rema AB, Rijo I, Agarunov A, Won H, Perera D, Brown DN, Samoila A, Jing X, Gedvilaite E, Yang JL, Stephens DP, Dix JM, DeGroat N, Nafa K, Syed A, Li A, Lebow ES, Bowman AS, Ferguson DC, Liu Y, Mata DA, Sharma R, Yang SR, Bale T, Benhamida JK, Chang JC, Dogan S, Hameed MR, Hechtman JF, Moung C, Ross DS, Vakiani E, Vanderbilt CM, Yao J, Razavi P, Smyth LM, Chandarlapaty S, Iyer G, Abida W, Harding JJ, Krantz B, O’Reilly E, Yu HA, Li BT, Rudin CM, Diaz L, Solit DB, Arcila ME, Ladanyi M, Loomis B, Tsui D, Berger MF, Zehir A, Benayed R. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat Commun. 2021 Jun 18;12(1):3770. doi: 10.1038/s41467-021-24109-5.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018;2018:PO.17.00160. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23. PMID: 29376144; PMCID: PMC5785105.


Publications on PubMed

Visit PubMed for a full listing of Dr. Brannon’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Angela Rose Brannon discloses the following relationships and financial interests:

  • Johnson & Johnson

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures